In a multicenter randomized phase 3 trial, stapokibart, a humanized monoclonal antibody that targets IL-4R alpha, significantly improved daily nasal and ocular symptom scores during the pollen phase in patients with moderate-to-severe seasonal allergic rhinitis.
- Yuan Zhang
- Jingyun Li
- Luo Zhang
